Pages that link to "Q53556305"

The following pages link to Phase I clinical study with multiple peptide vaccines in combination with tetanus toxoid and GM-CSF in advanced-stage HLA-A*0201-positive melanoma patients. (Q53556305):

Displaying 13 items.

• Germ Line-governed Recognition of a Cancer Epitope by an Immunodominant Human T-cell Receptor (Q27656470) (← links)
• T-cell Receptor-optimized Peptide Skewing of the T-cell Repertoire Can Enhance Antigen Targeting (Q27672418) (← links)
• Systematic review of the use of granulocyte-macrophage colony-stimulating factor in patients with advanced melanoma (Q28067023) (← links)
• Modification of MHC anchor residues generates heteroclitic peptides that alter TCR binding and T cell recognition (Q33635226) (← links)
• Monocytic CCR2(+) myeloid-derived suppressor cells promote immune escape by limiting activated CD8 T-cell infiltration into the tumor microenvironment (Q35783465) (← links)
• Trial watch: Peptide vaccines in cancer therapy (Q36476100) (← links)
• Nano-particle vaccination combined with TLR-7 and -9 ligands triggers memory and effector CD8⁺ T-cell responses in melanoma patients (Q36547213) (← links)
• Lessons from cancer immunoediting in cutaneous melanoma (Q38038176) (← links)
• In silico analysis to identify vaccine candidates common to multiple serotypes of Shigella and evaluation of their immunogenicity. (Q38648043) (← links)
• Lack of anti-tumour reactivity despite enhanced numbers of circulating natural killer T cells in two patients with metastatic renal cell carcinoma (Q39644938) (← links)
• Peptide Super-Agonist Enhances T-Cell Responses to Melanoma (Q64097880) (← links)
• MART-1- and gp100-expressing and -non-expressing melanoma cells are equally proliferative in tumors and clonogenic in vitro (Q85084285) (← links)
• TCR-induced alteration of primary MHC peptide anchor residue (Q92040061) (← links)